Enhanced clinical decisions for management of benign prostatic hyperplasia using patient-reported outcomes: protocol for a prospective observational study.
Lower urinary tract symptoms
Patient Reported Outcome Measures
Prostatic Hyperplasia
Qualitative Research
Symptom Assessment
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
21 May 2024
21 May 2024
Historique:
received:
22
04
2024
accepted:
15
05
2024
medline:
22
5
2024
pubmed:
22
5
2024
entrez:
21
5
2024
Statut:
epublish
Résumé
Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) significantly impact quality of life among older men. Despite the prevalent use of the American Urological Association Symptom Index (AUA-SI) for BPH, this measure overlooks key symptoms such as pain and incontinence, underscoring the need for more comprehensive patient-reported outcome (PRO) tools. This study aims to integrate enhanced PROs into routine clinical practice to better capture the spectrum of LUTS, thereby improving clinical outcomes and patient care. This prospective observational study will recruit men with LUTS secondary to BPH aged ≥ 50 years from urology clinics. Participants will be stratified into medical and surgical management groups, with PRO assessments scheduled at regular intervals to monitor LUTS and other health outcomes. The study will employ the LURN Symptom Index (SI)-29 alongside the traditional AUA-SI and other non-urologic PROs to evaluate a broad range of symptoms. Data on comorbidities, symptom severity, and treatment efficacy will be collected through a combination of electronic health records and PROs. Analyses will focus on the predictive power of these tools in relation to symptom trajectories and treatment responses. Aims are to: (1) integrate routine clinical tests with PRO assessment to enhance screening, diagnosis, and management of patients with BPH; (2) examine psychometric properties of the LURN SIs, including test-retest reliability and establishment of clinically meaningful differences; and (3) create care-coordination recommendations to facilitate management of persistent symptoms and common comorbidities measured by PROs. By employing comprehensive PRO measures, this study expects to refine symptom assessment and enhance treatment monitoring, potentially leading to improved personalized care strategies. The integration of these tools into clinical settings could revolutionize the management of LUTS/BPH by providing more nuanced insights into patient experiences and outcomes. The findings could have significant implications for clinical practices, potentially leading to updates in clinical guidelines and better health management strategies for men with LUTS/BPH. This study is registered in ClinicalTrials.gov (NCT05898932).
Sections du résumé
BACKGROUND
BACKGROUND
Lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) significantly impact quality of life among older men. Despite the prevalent use of the American Urological Association Symptom Index (AUA-SI) for BPH, this measure overlooks key symptoms such as pain and incontinence, underscoring the need for more comprehensive patient-reported outcome (PRO) tools. This study aims to integrate enhanced PROs into routine clinical practice to better capture the spectrum of LUTS, thereby improving clinical outcomes and patient care.
METHODS
METHODS
This prospective observational study will recruit men with LUTS secondary to BPH aged ≥ 50 years from urology clinics. Participants will be stratified into medical and surgical management groups, with PRO assessments scheduled at regular intervals to monitor LUTS and other health outcomes. The study will employ the LURN Symptom Index (SI)-29 alongside the traditional AUA-SI and other non-urologic PROs to evaluate a broad range of symptoms. Data on comorbidities, symptom severity, and treatment efficacy will be collected through a combination of electronic health records and PROs. Analyses will focus on the predictive power of these tools in relation to symptom trajectories and treatment responses. Aims are to: (1) integrate routine clinical tests with PRO assessment to enhance screening, diagnosis, and management of patients with BPH; (2) examine psychometric properties of the LURN SIs, including test-retest reliability and establishment of clinically meaningful differences; and (3) create care-coordination recommendations to facilitate management of persistent symptoms and common comorbidities measured by PROs.
DISCUSSION
CONCLUSIONS
By employing comprehensive PRO measures, this study expects to refine symptom assessment and enhance treatment monitoring, potentially leading to improved personalized care strategies. The integration of these tools into clinical settings could revolutionize the management of LUTS/BPH by providing more nuanced insights into patient experiences and outcomes. The findings could have significant implications for clinical practices, potentially leading to updates in clinical guidelines and better health management strategies for men with LUTS/BPH.
TRIAL REGISTRATION
BACKGROUND
This study is registered in ClinicalTrials.gov (NCT05898932).
Identifiants
pubmed: 38773430
doi: 10.1186/s12894-024-01500-0
pii: 10.1186/s12894-024-01500-0
doi:
Banques de données
ClinicalTrials.gov
['NCT05898932']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
110Subventions
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Organisme : NIH HHS
ID : R01 DK130963-01A1
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Urologic Diseases in America P: UDA Data Report: Epidemiology of non-malignant urologic disease in the United States: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2003; 2023.
Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, Wilt TJ. Management of lower urinary tract symptoms attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11–9.
doi: 10.1097/JU.0000000000003698
pubmed: 37706750
Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, Malde S, Mamoulakis C, Rieken M, Sakalis VI, et al. Summary Paper on the 2023 European Association of Urology Guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol. 2023;84(2):207–22.
doi: 10.1016/j.eururo.2023.04.008
pubmed: 37202311
Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2021;127(6):722–8.
doi: 10.1111/bju.15286
pubmed: 33124118
Barry MJ, Fowler FJ Jr., O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549–57. discussion 1564.
doi: 10.1016/S0022-5347(17)36966-5
pubmed: 1279218
Glaser AP, Mansfield S, Smith AR, Helfand BT, Lai HH, Sarma A, Yang CC, Taddeo M, Clemens JQ, Cameron AP, et al. Impact of Sleep Disturbance, physical function, depression and anxiety on male lower urinary tract symptoms: results from the symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). J Urol. 2022;208(1):155–63.
doi: 10.1097/JU.0000000000002493
pubmed: 35212573
pmcid: 9336513
Helfand BT, Smith AR, Lai HH, Yang CC, Gore JL, Erickson BA, Kreder KJ, Cameron AP, Weinfurt KP, Griffith JW, et al. Prevalence and characteristics of urinary incontinence in a treatment seeking male prospective cohort: results from the LURN Study. J Urol. 2018;200(2):397–404.
doi: 10.1016/j.juro.2018.02.075
pubmed: 29477718
pmcid: 6145092
Glaser AP, Kristof TW, Judge C, Javitch G, Hirsch S, Talaty P, Helfand BT, Smith AR, Griffith JW. The 10-item LURN Symptom Index (LURN SI-10) detects additional symptoms and shows convergent validity with the IPSS in men presenting with lower urinary tract symptoms. Urology. 2023;171:184–9.
doi: 10.1016/j.urology.2022.10.019
pubmed: 36370771
Hines L, Mali K, Campbell T, Jain R, Quarrier SO. Advancing Holmium Laser Enucleation of the prostate outcomes reporting: an Assessment of patient-reported outcomes in the literature. Urology; 2024.
Yaxley JW, Coughlin GD, Chambers SK, Occhipinti S, Samaratunga H, Zajdlewicz L, Dunglison N, Carter R, Williams S, Payton DJ, et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study. Lancet. 2016;388(10049):1057–66.
doi: 10.1016/S0140-6736(16)30592-X
pubmed: 27474375
Barnard J, Liaw A, Gelman J. Long-term follow-up suggests high satisfaction rates for bulbomembranous radiation-induced urethral stenoses treated with anastomotic urethroplasty. World J Urol. 2023;41(7):1905–12.
doi: 10.1007/s00345-023-04429-5
pubmed: 37314572
pmcid: 10352169
Cella D, Smith AR, Griffith JW, Flynn KE, Bradley CS, Gillespie BW, Kirkali Z, Talaty P, Jelovsek JE, Helfand BT, et al. A new outcome measure for LUTS: symptoms of lower urinary tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire. Neurourol Urodyn. 2019;38(6):1751–9.
doi: 10.1002/nau.24067
pubmed: 31225927
pmcid: 6660359
Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, Helfand BT, Talaty P, et al. A new brief Clinical Assessment of Lower urinary tract symptoms for women and men: LURN SI-10. J Urol. 2020;203(1):164–70.
doi: 10.1097/JU.0000000000000465
pubmed: 31364922
Weinfurt KP, Griffith JW, Flynn KE, Cella D, Bavendam T, Wiseman JB, Andreev VP, Lai HH, Liu AB, Kirkali Z, et al. The Comprehensive Assessment of Self-reported urinary symptoms: a New Tool for Research on subtypes of patients with lower urinary tract symptoms. J Urol. 2019;201(6):1177–83.
doi: 10.1097/JU.0000000000000140
pubmed: 30730410
pmcid: 6573020
Amundsen CL, Helmuth ME, Smith AR, DeLancey JOL, Bradley CS, Flynn KE, Kenton KS, Henry Lai H, Cella D, Griffith JW, et al. Longitudinal changes in symptom-based female and male LUTS clusters. Neurourol Urodyn. 2020;39(1):393–402.
doi: 10.1002/nau.24219
pubmed: 31765491
Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP. Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int. Suppl 2009;3:24–32.
doi: 10.1111/j.1464-410X.2009.08438.x
Viktrup L, Hayes RP, Wang P, Shen W. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urol. 2012;12:30.
doi: 10.1186/1471-2490-12-30
pubmed: 23134716
pmcid: 3503561
Administration FD. Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. In: 2018: Workshop date: October (pp. 15–16). 2018.
Suri H. Purposeful sampling in qualitative research synthesis. Qualitative Res J. 2011;11:63–75.
doi: 10.3316/QRJ1102063
Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, et al. The patient-reported outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010;63(11):1179–94.
doi: 10.1016/j.jclinepi.2010.04.011
pubmed: 20685078
pmcid: 2965562
Guy W. ECDEU assessment manual for psychopharmacology. Rockville, Md: National Institute of Mental Health; 1976.
Eating at America’s Table Study. Quick Food Scan. [Accessed April 19, 2024]. [ https://epi.grants.cancer.gov/diet/shortreg/instruments/percent-energy-from-fat-screener.pdf ]
Bright E, Cotterill N, Drake M, Abrams P. Developing and validating the International Consultation on Incontinence Questionnaire bladder diary. Eur Urol. 2014;66(2):294–300.
doi: 10.1016/j.eururo.2014.02.057
pubmed: 24647230
Bright E, Cotterill N, Drake M, Abrams P. Developing a validated urinary diary: phase 1. Neurourol Urodyn. 2012;31(5):625–33.
doi: 10.1002/nau.21254
pubmed: 22275270
Spiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, Whitman C, Khanna PP, Paz SH, Hays T, Reise S, Khanna D. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014;109(11):1804–14.
doi: 10.1038/ajg.2014.237
pubmed: 25199473
pmcid: 4285435
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319–26.
doi: 10.1038/sj.ijir.3900472
pubmed: 10637462
Rosen RC, Catania JA, Althof SE, Pollack LM, O’Leary M, Seftel AD, Coon DW. Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urology. 2007;69(5):805–9.
doi: 10.1016/j.urology.2007.02.036
pubmed: 17482908
Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, Khajehdehi A, Shapiro CM. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812–21.
doi: 10.1097/ALN.0b013e31816d83e4
pubmed: 18431116
Lai JS, Wagner LI, Jacobsen PB, Cella D. Self-reported cognitive concerns and abilities: two sides of one coin? Psychooncology. 2014;23(10):1133–1141.
Atkinson TM, Schwartz CE, Goldstein L, Garcia I, Storfer DF, Li Y, Zhang J, Bochner BH, Rapkin BD. Perceptions of Response Burden Associated with Completion of patient-reported outcome assessments in Oncology. Value Health. 2019;22(2):225–30.
doi: 10.1016/j.jval.2018.07.875
pubmed: 30711068
Koo TK, Li MY. A Guideline of selecting and reporting Intraclass correlation coefficients for Reliability Research. J Chiropr Med. 2016;15(2):155–63.
doi: 10.1016/j.jcm.2016.02.012
pubmed: 27330520
pmcid: 4913118
Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E, Lepor H. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154(5):1770–4.
doi: 10.1016/S0022-5347(01)66780-6
pubmed: 7563343
Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: confirmation through another look. Expert Rev Pharmacoecon Outcomes Res. 2004;4(5):581–5.
doi: 10.1586/14737167.4.5.581
pubmed: 19807551
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.
doi: 10.1097/01.MLR.0000062554.74615.4C
pubmed: 12719681
Salmona M, Lieber E, Kaczynski D. Qualitative and mixed methods data analysis using dedoose: a Practical Approach for Research across the Social Sciences. Sage; 2019.
Viktrup L, Hayes RP, Wang P, Shen W. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. BMC Urol. 2012;12(1):30.
doi: 10.1186/1471-2490-12-30
pubmed: 23134716
pmcid: 3503561
Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd edition). Hillsdale, NJ: L. Erlbaum Associates; 1988.
Bonett DG. Sample size requirements for estimating intraclass correlations with desired precision. Stat Med. 2002;21(9):1331–5.
doi: 10.1002/sim.1108
pubmed: 12111881